Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects

Tyck till om SwePub Sök här!

Koumarianou, AnnaAttikon Univ Hosp, Hematol Oncol Unit, Dept Internal Med 4, GR-12462 Athens, Greece. (författare)

Temozolomide in Advanced Neuroendocrine Neoplasms : Pharmacological and Clinical Aspects

Alkylating agents, such as streptozocin and dacarbazine, have been reported as active in neuroendocrine neoplasms (NENs). Temozolomide (TMZ) is an oral, potentially less toxic derivative of dacarbazine, which has shown activity both as a single agent and in combination with other drugs. Nevertheless, its role in NENs has not been well defined. Several retrospective and prospective phase I-II studies have been published describing its use in a variety of NENs. In a retrospective series, the combination of capecitabine and TMZ was reported to be associated with a particularly high tumour response in pancreatic NENs as a first-line treatment. Although in NENs, determination of the CP-nnethylguanineDNA methyltransferase (MGMT) status has been suggested as a predictive biomarker of response, its role still remains investigational, awaiting validation along with the establishment of the optimal detection method. Metronomic schedules have been reported to potentially overcome MGMT-related drug resistance. Toxicity is manageable if well monitored. We reviewed the literature regarding pharmacological and clinical aspects of TMZ, focusing on specific settings of NENs, different schedules, toxicity and safety profiles, and potential predictive biomarkers of response.

Kaltsas, GregoryNatl Tech Univ Athens, Dept Pathophysiol, Endocrine Unit, Athens, Greece. (författare)
Kulke, Matthew H.Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. (författare)
Öberg, KjellUppsala universitet,Endokrin Onkologi(Swepub:uu)kjellob (författare)
Strosberg, Jonathan R.Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. (författare)
Spada, FrancescaEuropean Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy. (författare)
Galdy, SalvatoreEuropean Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy. (författare)
Barberis, MassimoEuropean Inst Oncol, Div Pathol, IT-20141 Milan, Italy. (författare)
Fumagalli, CaterinaEuropean Inst Oncol, Div Pathol, IT-20141 Milan, Italy. (författare)
Berruti, AlfredoUniv Brescia, Dipartimento Specialita Med Chirurg Sci Radiol &, Azienda Osped Spedali Civili, Brescia, Italy. (författare)
Fazio, NicolaEuropean Inst Oncol, Gastrointestinal Med Oncol & Neuroendocrine Tumor, IT-20141 Milan, Italy. (författare)
Attikon Univ Hosp, Hematol Oncol Unit, Dept Internal Med 4, GR-12462 Athens, Greece.Natl Tech Univ Athens, Dept Pathophysiol, Endocrine Unit, Athens, Greece. (creator_code:org_t)

Av författaren/redakt...: Koumarianou, Ann ...; Kaltsas, Gregory; Kulke, Matthew H ...; Öberg, Kjell; Strosberg, Jonat ...; Spada, Francesca; visa fler...; Galdy, Salvatore; Barberis, Massim ...; Fumagalli, Cater ...; Berruti, Alfredo; Fazio, Nicola; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.